Drug Information

Back

Taxotere

Brand Name:Taxotere Trade Name:docetaxel
FDA Approved For:Breast Cancer: TAXOTERE (docetaxel) for Injection Concentrate is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior chemotherapy. Non-Small Cell Lung Cancer: TAXOTERE (docetaxel) for Injection Concentrate is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of prior platinum-based chemotherapy. Pediatric Use:The safety and effectiveness of TAXOTERE in pediatric patients have not been established.
Carcinogen:No studies have been conducted to assess the carcinogenic potential of TAXOTERE. Mutagen:TAXOTERE has been shown to be clastogenic in the in vitro chromosome aberration test in CHO-K1 cells and in the in vivo micronucleus test in the mouse, but it did not induce mutagenicity in the Ames test or the CHO/HGPRT gene mutation assays.
Manufacturer and/or Distributor:Aventis Pharmaceutical

Adverse Reactions:

For a complete list of adverse reactions please click on the link "More Information" for this drug.)

More Information

Back